WVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Wave Life Sciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$3.17+0.04 (+1.28%)
Close on Oct 19, 2026
- Market cap
- $646.71M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$4.64 (−59.41%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Wave Life Sciences, Inc. saw revenue fall 60.5% to $42.73M over fiscal 2025. Free cash flow was -$193.15M.
Revenue
$42.73M
-60.5% vs. a year earlier
Operating income
-$217.92M
TTM Q2 2026
Free cash flow
-$193.15M
TTM Q2 2026
EPS, diluted
-$1.08
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $646.71M
- P/E ratio
- –
- Price to sales
- 15.14
- Price to book
- 1.43
- Dividend yield
- –
- Free cash flow yield
- -29.87%
Fundamentals
- Revenue
- $42.73M
- Net income
- -$202.47M
- EPS, diluted
- -$1.08
- Free cash flow
- -$193.15M
- Book value per share
- $2.22
- Diluted shares
- 204M
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
–
Operating income
-$217.92M
Net income
-$202.47M
EPS, diluted
-$1.08
Free cash flow
-$193.15M
Reported periodTrailing twelve months